A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

Advances in Therapy - United States
doi 10.1007/s12325-019-00979-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

BioDrugs
MedicineBiotechnologyPharmacology
2016English

A Budget Impact Analysis of Adalimumab Biosimilar: The Italian Context

AboutOpen
2019English

Physicochemical and Functional Characterization of a Biosimilar Adalimumab ZRC-3197

Biosimilars
2014English

Adalimumab: A Review of the Reference Product and Biosimilars

Biosimilars
2016English

The Love of the Future: Openness/Totality

Stasis
Philosophy
2016English

Case Study: Biosimilar Anti TNFalpha (Adalimumab) Analysis of Fc Effector Functions

BMC Proceedings
BiochemistryMedicineGeneticsMolecular Biology
2013English

First-Line Interactive Wound Dressing Update: A Comprehensive Review of the Evidence

Frontiers in Pharmacology
Pharmacology
2020English

The First Biosimilar Approved for the Treatment of Osteoporosis: Results of a Comparative Pharmacokinetic/Pharmacodynamic Study

Osteoporosis International
MedicineEndocrinologyMetabolismDiabetes
2018English

Psy156 - Quids In? – A Review of Whether Potential Blockbuster Savings From Biosimilar Adalimumab Should Be Reinvested in Other Disease Areas?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy